Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jacob Van Naarden"'
Autor:
Jack Knorr, Russell Perry, Peter Chen, Corey Hebert, Richard E. Higgs, Mark D. Williams, Joseph Boscia, Bharat Mocherla, Masoud Azizad, Princy Kumar, Robert L. Gottlieb, Paul Klekotka, Dipak R. Patel, Ajay Nirula, Imad Shawa, Andra L. Blomkalns, Andrew C. Adams, Gregory D. Huhn, Kenneth L. Custer, Lei Shen, Timothy R. Holzer, Jason Morris, Philip J. Ebert, Andrew E. Schade, Jacob Van Naarden, Blaze investigators, Gerard J. Oakley, Jose Cardona, Janelle Sabo, Matan C. Dabora, Daniel Skovronsky, Chad Crystal, Barry Heller, Awawu Igbinadolor, Michael Dougan
Publikováno v:
Clinical Infectious Diseases. 75:e440-e449
Background Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods This Phase 3 portion of the BLAZE-1 tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c671bc65b6856e2a675f8baf6d6b7e3
https://doi.org/10.1093/cid/ciab912
https://doi.org/10.1093/cid/ciab912
Autor:
Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller
Publikováno v:
The New England Journal of Medicine
Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163d2b1d9fb708ea8c2b335a117a4a4b
https://doi.org/10.1056/nejmoa2102685
https://doi.org/10.1056/nejmoa2102685
Autor:
Ajay Nirula, Jason Morris, Valentina Stosor, Gerard J. Oakley, Robert L. Gottlieb, Gregory D. Huhn, Jacob Van Naarden, Bharat Mocherla, Peter Chen, Joseph Boscia, Janelle Sabo, Daniel Skovronsky, Dipak R. Patel, Kenneth L. Custer, Michael Durante, Lei Shen, Paul Klekotka, Imad Shawa, Andrew E. Schade, Andrew C. Adams, Jose Cardona, Barry Heller
Publikováno v:
New England Journal of Medicine
The New England Journal of Medicine
The New England Journal of Medicine
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d6e5ff14295583c7465beec9f8d437a
https://doi.org/10.1056/nejmoa2029849
https://doi.org/10.1056/nejmoa2029849
Autor:
Andrew C. Adams, Jose Cardona, Barry Heller, Nicole L. Kallewaard, Jason Morris, Michael Durante, Bharat Mocherla, Richard E. Higgs, Valentina Stosor, Daniel Skovronsky, Joseph Boscia, Paul Klekotka, Princy Kumar, Imad Shawa, Robert L. Gottlieb, Ajay Nirula, Timothy R. Holzer, Lei Shen, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Dipak R. Patel, Kenneth L. Custer, Andrew E. Schade, Janelle Sabo, Peter Chen, Gregory D. Huhn
Publikováno v:
JAMA. 325(7)
Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with bamlani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bce1969b4b650dacd3943f737ab763cf
https://pubmed.ncbi.nlm.nih.gov/33475716
https://pubmed.ncbi.nlm.nih.gov/33475716
Autor:
Myron S, Cohen, Ajay, Nirula, Mark J, Mulligan, Richard M, Novak, Mary, Marovich, Catherine, Yen, Alexander, Stemer, Stockton M, Mayer, David, Wohl, Blair, Brengle, Brian T, Montague, Ian, Frank, Russell J, McCulloh, Carl J, Fichtenbaum, Brad, Lipson, Nashwa, Gabra, Julio A, Ramirez, Christine, Thai, Wairimu, Chege, Margarita M, Gomez Lorenzo, Nirupama, Sista, Jennifer, Farrior, Meredith E, Clement, Elizabeth R, Brown, Kenneth L, Custer, Jacob, Van Naarden, Andrew C, Adams, Andrew E, Schade, Matan C, Dabora, Jack, Knorr, Karen L, Price, Janelle, Sabo, Jay L, Tuttle, Paul, Klekotka, Lei, Shen, Daniel M, Skovronsky, George, Taffet
Publikováno v:
JAMA. 326:46
IMPORTANCE Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0258235561f5370f7c10ea27186c4bbf
https://doi.org/10.1001/jama.2021.8828
https://doi.org/10.1001/jama.2021.8828